

May 5, 2026

# QuidelOrtho First Quarter 2026 Financial Results

# Forward-Looking Statements and Non-GAAP Financial Measures

**Forward-Looking Statements:** This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho's commercial and other strategic goals, financial guidance for 2026 and related assumptions and other future financial condition and operating results, including growth expectations and expected results of operations, financial position or cost-savings and operational improvement initiatives, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words "may," "will," "could," "would," "should," "might," "expect," "anticipate," "believe," "estimate," "plan," "intend," "goal," "project," "strategy," "future," "continue," "aim," "strive," "seek" or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho's management as of today and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results or outcomes to differ from those set forth or implied in the forward-looking statements: fluctuations in demand for QuidelOrtho's non-respiratory and respiratory products; supply chain, production, logistics, distribution and labor disruptions and challenges; inability to successfully identify, consummate or realize the anticipated benefits of strategic transactions, strategic restructurings, divestitures, spin-offs or discontinuances of certain business operations, or debt financings, on the anticipated timelines, or at all; delays in the development of or failures or delays in the receipt of approvals for new or enhanced products; failure of new products and services to be commercially viable or accepted; changes in reimbursement rates for our products, including reimbursement rate reductions proposed by the China National Health Security Administration; disruptions and challenges related to the ongoing conflicts in the Middle East; and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those arising from the effects of announced or future or amended tariffs, trade policies, investigations, global trade relations and other tariff-related developments, as well as those discussed in QuidelOrtho's Annual Report on Form 10-K for the fiscal year ended December 28, 2025 and subsequent reports filed with the Securities and Exchange Commission (the "Commission"), including under Part I, Item 1A, "Risk Factors" of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date hereof. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this presentation, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.

**Non-GAAP Financial Measures:** This presentation contains financial measures that are considered non-GAAP financial measures under applicable rules and regulations of the Commission, including but not limited to "constant currency revenue changes," "recurring revenue," "adjusted operating expenses," "adjusted operating expense changes," "adjusted EBITDA," "adjusted EBITDA margin," "adjusted gross profit margin," "adjusted gross profit margin changes," "adjusted diluted loss per share," "adjusted diluted loss per share changes," "adjusted tax rate," "free cash flow" and other non-GAAP financial measures included in the reconciliation tables in the Appendix of this presentation. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures eliminate impacts of certain non-cash, unusual or other items that the Company does not consider indicative of its ongoing operating performance, and the Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results and comparison to competitors' operating results. The Company's definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and reports filed with the Commission in their entirety. Reconciliations of the historical non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the Appendix or elsewhere within this presentation.

# Basis of Presentation

- 2026 financials are as of the three months ended March 29, 2026 and 2025 financials are as of the three months ended March 30, 2025.
- Revenue growth rates are shown on a constant currency basis unless otherwise noted. The term "constant currency" means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period.
- Adjusted diluted loss per share in 2026 and adjusted diluted earnings per share in 2025 are non-GAAP measures, which are calculated based on weighted-average shares outstanding – diluted of 68.2 million and 67.9 million for 2026 and 2025, respectively.
- Recurring revenue, a non-GAAP measure, means revenues from sales of our assays, reagents, consumables and services, and excludes instruments.
- For full-year 2026 financial guidance, a reconciliation of forward-looking non-GAAP measures, including adjusted EBITDA, adjusted EBITDA margin, adjusted diluted earnings per share and free cash flow, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. We are not, without unreasonable effort, able to reliably predict the impact of impairment charges and related tax benefits and other non-recurring adjustments. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. In addition, the Company believes any such reconciliation would imply a degree of precision and certainty that could be confusing to investors.
- Net debt to adjusted EBITDA is based on management estimates for adjusted EBITDA and net debt as of March 29, 2026.
- Pro forma debt leverage ratio includes pro forma EBITDA adjustments as of March 29, 2026, as defined and permitted under the terms of our credit agreement.

# Q1 2026 Revenue Highlights






**Across  
Key Healthcare  
Settings**



**Across  
Regions**



**Highly  
Recurring  
Revenue**



# Q1 2026 Financial Results

## Adj Operating Expenses

\$227M

(2)% y/y

### SM&A

\$185M | 3% y/y

### R&D

\$43M | (19)% y/y

## Adj EBITDA

\$109M

Adj. EBITDA Margin

17.5%

### Adj Gross Profit Margin

43.8% | (630) bps y/y

## Adj Diluted Loss Per Share

\$(0.04)

(105)% y/y

### Adj Tax Rate

24.5%

### Depreciation

\$66M

## Cash

\$140M

Free Cash Flow <sup>(a)</sup>

\$(67)M

### Total Net Debt

\$2.6B

### Net Debt to Adj EBITDA

4.8x

### Pro Forma Debt Leverage Under Credit Agreement

4.1x

(a) Free cash flow for the three months ended March 29, 2026, of \$(67) million represents \$(33) million of net cash used for operating activities less \$34 million of cash used for acquisitions of property, plant, equipment, investments and intangibles.

# FY 2026 Financial Guidance

## As of 5/5/26

Financial Guidance	FY 2026
Total Revenues (Reported)	\$2.70 - \$2.75B
Adjusted EBITDA	\$615 - \$630M
Adjusted EBITDA Margin	23%
Adjusted Diluted EPS	\$1.80 - \$2.00
Free Cash Flow	\$100 - \$120M

- Considering first-quarter 2026 performance and current market dynamics in China, the Company has updated its previously provided financial guidance as of 5/5/26. This guidance includes expected 2026 impact from the current draft of the China National Health Security Administration (“NHTSA”) IVD pricing guidelines. The Company cannot fully assess the impact until the final NHTSA guidelines and implementation timelines are confirmed.
- In addition, this guidance does not assume a significant, prolonged impact related to the Middle East conflict.
- Revenue assumptions for full-year 2026 include the wind-down of the U.S. Donor Screening business to be substantially complete by mid-year, and minimal revenue contribution from the LEX Diagnostics acquisition.
- Foreign currency exchange is expected to be neutral to full-year 2026 revenue based on currency rates as of March 29, 2026.
- Respiratory is assumed to be a typical flu season of 50-55 million annual market tests and COVID-19 revenue to be flat to FY 2025 at \$80 million.
- Depreciation is assumed to be \$250 million.
- Interest expense is assumed to be \$200 million.
- The effective tax rate is assumed to be 24%.
- Capital expenditures are assumed to be in the range of \$130-\$150 million, excluding instruments under reagent rental agreements.

# Appendix

# Non-GAAP Adjustments

In millions	Fiscal Quarter	
	Q1 2026	Q1 2025
Employee compensation charges	\$ 2.3	\$ —
Accelerated depreciation	2.0	—
Incremental depreciation on PP&E fair value adjustment	1.8	3.3
Amortization of deferred cloud computing implementation costs	0.7	0.3
Other adjustments	0.6	—
<b>Cost of sales, excluding amortization of intangibles</b>	<b>7.4</b>	<b>3.6</b>
Amortization of deferred cloud computing implementation costs	7.3	4.0
Employee compensation charges	3.0	—
Incremental depreciation on PP&E fair value adjustment	0.8	1.6
Other adjustments	3.4	1.2
<b>Selling, marketing and administrative</b>	<b>14.5</b>	<b>6.8</b>
Incremental depreciation on PP&E fair value adjustment	0.7	0.3
EU medical device regulation transition costs	0.7	0.2
Employee compensation charges	0.2	—
Other adjustments	0.7	—
<b>Research and development</b>	<b>2.3</b>	<b>0.5</b>
<b>Amortization of intangibles</b>	<b>46.8</b>	<b>48.0</b>
<b>Restructuring, integration and other charges</b>	<b>4.4</b>	<b>16.1</b>
<b>Other operating expenses</b>	<b>—</b>	<b>—</b>
<b>Increase to Operating (loss) income</b>	<b>75.4</b>	<b>75.0</b>
<b>Interest expense, net</b>	<b>—</b>	<b>—</b>
Loss (gain) on investments	0.9	(0.3)
<b>Other (income) expense, net</b>	<b>0.9</b>	<b>(0.3)</b>
<b>Increase to Loss before income taxes</b>	<b>76.3</b>	<b>74.7</b>
<b>Income tax impact of adjustments</b>	<b>13.1</b>	<b>(11.8)</b>
<b>Increase to Net loss</b>	<b>\$ 89.4</b>	<b>\$ 62.9</b>

# Q1 2026 Non-GAAP Reconciliation

In millions	Fiscal Quarter Q1 2026			Fiscal Quarter Q1 2025		
	GAAP	Adjustments <sup>(1)</sup>	Non-GAAP	GAAP	Adjustments <sup>(1)</sup>	Non-GAAP
Gross profit	\$ 263.8	\$ 7.4	\$ 271.2	\$ 343.3	\$ 3.6	\$ 346.9
Selling, marketing and administrative	199.3	(14.5)	184.8	187.0	(6.8)	180.2
Research and development	44.9	(2.3)	42.6	53.2	(0.5)	52.7
Amortization of intangibles	46.8	(46.8)	—	48.0	(48.0)	—
Restructuring, integration and other charges	4.4	(4.4)	—	16.1	(16.1)	—
Other operating expenses	0.2	—	0.2	6.4	—	6.4
Operating (loss) income	(31.8)	75.4	43.6	32.6	75.0	107.6
Operating margin	(5.1)%		7.0 %	4.7 %		15.5 %
Interest expense, net	51.1	—	51.1	40.0	—	40.0
Other (income) expense, net	(3.4)	(0.9)	(4.3)	1.4	0.3	1.7
(Loss) income before income taxes	(79.5)	76.3	(3.2)	(8.8)	74.7	65.9
Provision for (benefit from) income taxes	12.3	(13.1)	(0.8)	3.9	11.8	15.7
<b>Net (loss) income</b>	<b>\$ (91.8)</b>	<b>\$ 89.4</b>	<b>\$ (2.4)</b>	<b>\$ (12.7)</b>	<b>\$ 62.9</b>	<b>\$ 50.2</b>

# Revenue by Geography

## Three Months Ended

In millions	2025				2026	First Quarter		
	Q1	Q2	Q3	Q4	Q1	Percent Change	Currency Impact	Constant Currency <sup>(1)</sup>
North America	\$406.7	\$310.7	\$381.4	\$390.1	\$328.9	(19.1)%	(0.2)%	(18.9)%
EMEA	88.9	87.3	91.8	92.7	92.5	4.0%	10.1%	(6.1)%
China	75.0	83.4	84.6	91.7	63.5	(15.3)%	3.7%	(19.0)%
JPAC	68.1	72.2	76.8	75.9	70.0	2.8%	(1.9)%	4.7%
Latin America	54.1	60.3	65.3	73.2	64.9	20.0%	10.7%	9.3%
<b>Total Revenue</b>	<b>\$692.8</b>	<b>\$613.9</b>	<b>\$699.9</b>	<b>\$723.6</b>	<b>\$619.8</b>	<b>(10.5)%</b>	<b>2.1%</b>	<b>(12.6)%</b>

## Year to Date

In millions	2025		
	6 Months	9 Months	Year
North America	\$717.4	\$1,098.8	\$1,488.9
EMEA	176.2	268.0	360.7
China	158.4	243.0	334.7
JPAC	140.3	217.1	293.0
Latin America	114.4	179.7	252.9
<b>Total Revenue</b>	<b>\$1,306.7</b>	<b>\$2,006.6</b>	<b>\$2,730.2</b>

# Revenue by Business Unit

## Three Months Ended

In millions	2025				2026	First Quarter		
	Q1	Q2	Q3	Q4	Q1	Percent Change	Currency Impact	Constant Currency <sup>(1)</sup>
Labs	\$373.0	\$369.7	\$373.8	\$389.2	\$353.1	(5.3)%	2.3%	(7.6)%
Immunohematology	128.5	132.3	142.0	141.0	138.3	7.6%	4.2%	3.4%
Donor Screening	12.8	13.3	14.7	11.8	7.8	(39.1)%	0.4%	(39.5)%
Point of Care <sup>(a)</sup>	170.9	93.0	164.6	173.1	112.8	(34.0)%	0.6%	(34.6)%
Molecular Diagnostics	7.6	5.6	4.8	8.5	7.8	2.6%	4.4%	(1.8)%
<b>Total Revenue</b>	<b>\$692.8</b>	<b>\$613.9</b>	<b>\$699.9</b>	<b>\$723.6</b>	<b>\$619.8</b>	<b>(10.5)%</b>	<b>2.1%</b>	<b>(12.6)%</b>

## Year to Date

In millions	2025		
	6 Months	9 Months	Year
Labs	\$742.7	\$1,116.5	\$1,505.7
Immunohematology	260.8	402.8	543.8
Donor Screening	26.1	40.8	52.6
Point of Care	263.9	428.5	601.6
Molecular Diagnostics	13.2	18.0	26.5
<b>Total Revenue</b>	<b>\$1,306.7</b>	<b>\$2,006.6</b>	<b>\$2,730.2</b>

(a) Point of Care revenue includes Triage revenue of \$31.0 million (no currency impact, reflecting \$31.0 million in constant currency) and \$33.2 million (\$1.2 million currency impact, reflecting \$34.4 million in constant currency) for the three months ended March 29, 2026 and March 30, 2025, respectively.

# Revenue by Respiratory and Non-Respiratory

## Three Months Ended

In millions	2025				2026	First Quarter		
	Q1	Q2	Q3	Q4	Q1	Percent Change	Currency Impact	Constant Currency <sup>(1)</sup>
Respiratory Revenue	\$119.8	\$46.7	\$112.3	\$123.3	\$67.9	(43.3)%	0.3%	(43.6)%
Non-Respiratory Revenue	573.0	567.2	587.6	600.3	551.9	(3.7)%	2.5%	(6.2)%
<b>Total Revenue</b>	<b>\$692.8</b>	<b>\$613.9</b>	<b>\$699.9</b>	<b>\$723.6</b>	<b>\$619.8</b>	<b>(10.5)%</b>	<b>2.1%</b>	<b>(12.6)%</b>

## Year to Date

In millions	2025		
	6 Months	9 Months	Year
Respiratory Revenue	\$166.5	\$278.8	\$402.1
Non-Respiratory Revenue	1,140.2	1,727.8	2,328.1
<b>Total Revenue</b>	<b>\$1,306.7</b>	<b>\$2,006.6</b>	<b>\$2,730.2</b>

# Non-GAAP Reconciliations – Adjusted EBITDA

In millions	Fiscal Quarter	
	Q1 2026	Q1 2025
<b>Net loss</b>	\$ (91.8)	\$ (12.7)
Depreciation and amortization	112.9	107.1
Interest expense, net	51.1	40.0
Provision for income taxes	12.3	3.9
Restructuring, integration and other charges	4.4	16.1
Amortization of deferred cloud computing implementation costs	8.0	4.3
Employee compensation charges	5.5	—
Loss (gain) on investments	0.9	(0.3)
EU medical device regulation transition costs	0.7	0.2
Other adjustments	4.7	1.2
<b>Adjusted EBITDA</b>	\$ <b>108.7</b>	\$ <b>159.8</b>



QuidelOrtho™

[quidelortho.com](http://quidelortho.com)